Entity

GLP-1

GLP-1 — glucagon-like peptide-1 (agonists). The drug class behind Ozempic and Wegovy — obesity and diabetes treatments reshaping pharma pipelines and food-industry forecasts.

As of 8 Oct 2026Last evidence 8 Oct 2026

What is happening now

  • WHO endorses lifestyle changes over GLP-1 drugs in child obesity fight

    Reported claim · first reported 7 Oct 2026 · 1 claim · best-carried claim: 2 separate publishers

  • FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

    Reported claim · first reported 30 Sept 2026 · 1 claim · best-carried claim: 3 separate publishers

All 2 events and claims involving GLP-1

What changed

  • Attention GLP-1 has 48 mentions in tracked coverage: too few to measure a trend.
  • State Changes between snapshots: cannot measure, no state history is kept for GLP-1 yet.
  • Claims 1 claim first reported since 7 Oct 2026.

How well we know this

318 documents · 95 publishers · 22% contain a typed assertion · last evidence 8 Oct 2026

  • Gap: assertion coverage 0.22: about 78% of mentions carry no typed assertion
  • Gap: 4 receipts withheld: no source link (the same rule the topic record applies)

In this snapshot’s daily coverage:

Reported alongside GLP-1

Names most often reported alongside it; bigger circles and heavier lines mean more shared documents. A dashed circle has no page of its own yet.

Eli LillyAINovo NordiskMounjaroZepboundDenmark
  • Eli Lilly · 89 shared documents
  • FDA · 85 shared documents · no page of its own yet
  • Glp-1s · 71 shared documents · no page of its own yet
  • AI · 62 shared documents
  • Novo Nordisk · 55 shared documents
  • Mounjaro · 51 shared documents
  • Zepbound · 44 shared documents
  • Buy · 37 shared documents · no page of its own yet
  • Denmark · 36 shared documents
  • Clinical Trial · 34 shared documents · no page of its own yet

GLP-1 has 48 mentions in tracked coverage. That is too few to measure a trend. Watch GLP-1 to hear when coverage grows, or request deeper coverage of GLP-1.

For developers

This page is also an object: GET https://sigb.ai/api/v1/node/e/6d911ae375a0bffac4f2f4c7 returns the same record as sb.node.v1. Or call the get_entity MCP tool at https://sigb.ai/api/mcp with name glp-1.

{
  "name": "glp-1",
  "label": "GLP-1",
  "asOf": "2026-10-08",
  "mentions": 48,
  "outlets": 32,
  "domains": 5,
  "node": {
    "id": "sb:e/6d911ae375a0bffac4f2f4c7",
    "schema": "sb.node.v1",
    "rest": "https://sigb.ai/api/v1/node/e/6d911ae375a0bffac4f2f4c7",
    "knowledgeCutoff": "2026-10-08T19:01:28.512480+00:00",
    "snapshot": "this deploy's committed data files (commit not exposed in this runtime)"
  },
  "coverageTrend": "too few mentions to measure",
  "whereFrom": {
    "level": "counts",
    "label": "48 mentions across 5 domains",
    "children": [
      {
        "level": "reports",
        "label": "6 reports drawn on this page, each with its link",
        "children": {
          "count": 6,
          "unfold": "expand=+1"
        }
      },
      {
        "level": "domains",
        "label": "5 coverage domains",
        "children": {
          "count": 5,
          "unfold": "expand=+1"
        }
      },
      {
        "level": "not shown",
        "label": "The other 42 mentions",
        "edge": "counted daily from tracked coverage; single mentions are not listed one by one"
      }
    ]
  }
}

The figures on this page, as data. The tool returns the full entity record.

Events involving GLP-1

Most-reported first, then newest. Registered events come from the event record; reported events are groups of claims about one occurrence. Claims are grouped when they were first reported within 2 days of each other and either name at least 2 of the same people, places or things besides this one, or share at least 25% of their wording. Each claim keeps its own record.

  • WHO endorses lifestyle changes over GLP-1 drugs in child obesity fight

    Reported claim · first reported 7 Oct 2026 · 1 claim · best-carried claim: 2 separate publishers

    corroborated

  • FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

    Reported claim · first reported 30 Sept 2026 · 1 claim · best-carried claim: 3 separate publishers

    corroborated

Walk the record from GLP-1

Open where it comes from, follow a claim or a related name, and use the trail to come back. Every step says what it is, how it stands and when. Machines read the same record.

GLP-1

Entity.

Evidence
318 documents · 95 separate publishers · a mention shows the name is in use, not that any claim about it is true
Standing
A name from our starting list; its record is kept up to date automatically from coverage
Time
first seen 6 Apr 2026, last seen 8 Oct 2026
Measured
22% of mentions say something specific about it; the rest only name it
As of
8 Oct 2026
12 links from here

Who it moves with: the 10 names are in the map above.

What is claimed about it (2)

  • Corroborated: Reported by three or more sources that did not copy each other.
  • Reported by two: Reported by two sources that did not copy each other.

Situations it is named in (0)

none on file at this cutoff

For machines: this record as JSON

Watch this

What the coverage says

Recent reporting that names GLP-1, newest first. Open any row to follow it to the original article. Sparse topics can mix unrelated senses of the word.

Evidence tiers: primary source = an official public record · attributed = a named outlet, receipt linked · lead = observed, not yet receipted.

Ask about GLP-1Watch GLP-1

Story momentum counts mentions in tracked coverage. Prices are the market’s own, cited with the venue. Informational only, not advice. As of 8 Oct 2026.